World Market for Antidepressants 2006; The

• 1.1 Aims And Scope of Antidepressants, 2006

• 2.1 The Global Cost of Depression
• 2.2 Overview of the Global Antidepressant Market
• 2.2 The Threat of Generics

• 3.1 What Is Depression?
• 3.2 Different Types Of Depression
  • 3.2.1 Major Depressive Disorder (MDD)
  • 3.2.2 Dysthymia
  • 3.2.3 Bipolar Disorder Is Not Depression
  • 3.2.4 Other Types Of Depression
• 3.3 Causes Of Depression
• 3.4 Age, Sex and Depressive Disorders
  • 3.4.1 Depression In Women
  • 3.4.2 Depression In Men
  • 3.4.3 Depression In The Elderly
• 3.5 The Receptor Hypothesis Of Depression
  • 3.5.1 Serotonin
  • 3.5.2 Norepinephrine (Noradrenaline)
  • 3.5.3 Dopamine
  • 3.5.4 Targets For Drug Development
• 3.6 Anxiety
• 3.7 Drug Therapies For Depression
  • 3.7.1 Monoamine Oxidase Inhibitors (Maois)
  • 3.7.2 Tricyclic Antidepressants (TCAs)
  • 3.7.3 Selective Serotonin Re-Uptake Inhibitors
  • 3.7.4 Selective Serotonin and Norepinephrine Re-Uptake Inhibitors
  • 3.7.5 Selective Catecholamine Reuptake Inhibitors
• 3.8 Leading Drugs In The Antidepressant Market and Their Mode Of Action

• 4.1 World Revenue Forecast For Leading Antidepressants
• 4.2 Market Share by Drug
• 4.3 Patent Issues and Generic Encroachment
• 4.4 More Sophisticated Marketing is Required to Drive the Market
  • 4.4.1 Regulatory Restraints Limit Marketing Options
  • 4.4.2 Tapping the Untapped - Can Antidepressant Uptake be Increased by Marketing?
  • 4.4.3 New Indications and Off-Label Use Can Extend an Antidepressant's Lifetime
  • 4.4.4 Compliance is a Major Concern
  • 4.4.5 New Formulations Will Provide a Small Amount of Protection from Generics
  • 4.4.6 Pricing
• 4.5 The Psychology of Drug Prescription
• 4.6 SSRIs Dominate But Will Lose their Majority Market Share by 2010
• 4.7 SSNRIs Will Increase Their Market Share
• 4.8 Other Modes of Action Should Hold their Market Share But May Lose Out to New Treatments
• 4.9 Individual Forecasts For SSRIs
  • 4.9.1 Zoloft (Pfizer)
  • 4.9.2 Paxil/Seroxat (GSk)
  • 4.9.3 Lexapro And Celexa (Lundbeck A/S and Forest Laboratories)
  • 4.9.4 Prozac (Lilly)
  • 4.9.5 Luvox (Astellas Pharma)
• 4.10 Effexor Is Well-Established But Faces a Challenge from Cymbalta
• 4.10.1 Effexor (Wyeth)
• 4.10.2 Cymbalta (Lilly)
• 4.11 Other Classes of Antidepressants
• 4.11.1 Wellbutrin (GSK)
• 4.11.2 Remeron (Azko Nobel)
• 4.12 The Antidepressant Market Will Become Extremely Dynamic Because of the Next Generation of Therapies

• 5.1 United States
• 5.2 Japan - A Model for Market Expansion
• 5.3 Europe
• 5.4 Potential Markets Will Be Hard to Find

• 6.1 SWOT Analysis of the Antidepressant Market
• 6.2 Reduction in Side Effects
• 6.3 Treatment Resistant Depression (TRD) is a Large Untapped Market
• 6.4 The Lag Period Before Drug Effectiveness is a Restraint on Compliance
• 6.5 Alternative Treatments For Depression Present Possible Threats and Emphasize Unmet Needs
  • 6.5.1 St. John's Wort
  • 6.5.2 Electroconvulsive Therapy (ECT)
  • 6.5.3 Psychotherapy
• 6.6 Summary: New Antidepressants Need to Reduce the Lag Time

• 7.1 Triple Uptake Inhibitors - the Next Step From SSNRIs
  • 7.1.1 (R)-Sibutramine Metabolite (Sepracor)
  • 7.1.2 DOV 216,303 and DOV 21,947 (Merck)
  • 7.1.3 NS2359 and Radafaxine
• 7.2 5HT Antagonists and Agonists
  • 7.2.1 Gepirone ER
  • 7.2.2 Vilazodone
  • 7.2.3 PRX-00023
• 7.3 Neurokinin Receptor Antagonists
  • 7.3.1 Saredutant Potentially Offers a New Approach
  • 7.3.2 GSK Has Three NK Receptor Antagonists in Development For Depression
• 7.4 CRF Antagonists
• 7.5 Other Approaches May Still Yield Results
  • 7.5.1 Valdoxan
  • 7.5.2 Beta Adrenergic Receptor Agonists (SR58878)
  • 7.5.3 Monoamine Oxidase Inhibitors
• 7.6 A Varied And Competitive Pipeline For New Antidepressants
• 7.7 Are Unmet Needs Likely To Be Met Soon? Valdoxin And Saradutant Are The Most Promising Candidates

• 8.1 The Antidepressant Market Faces an Uncertain Future

List of Tables

• Table 1.1 Leading Drugs in the Antidepressant Market, 2005
• Table 2.1 Main Causes of Disability in Disability Adjusted Life Years (DALY) for Adults 15-59, 2002
• Table 3.1 Top Ten Antidepressants in the World and their Mode of Action, 2005
• Table 4.1 World Revenues ($m) for Antidepressant Drugs, 2003-2010
• Table 4.2 Patent Expiry for Antidepressants and Selected Formulations, 2005
• Table 4.3 FDA Approved Indications for Antidepressants, 2005
• Table 4.4 Patent Expiry for Extended Release Formulations (US patents), 2005
• Table 4.5 World Zoloft Revenues ($m), 2003-2010
• Table 4.6 World Paxil Revenues ($m), 2003-2010
• Table 4.7 World Celexa Revenues ($m), 2003-2010
• Table 4.8 World Lexapro Revenues ($m), 2003-2010
• Table 4.9 World Prozac Revenues ($m), 2003-2010
• Table 4.10 World Luvox Revenues ($m), 2003-2010
• Table 4.11 World Effexor Revenues ($m), 2003-2010
• Table 4.12 World Cymbalta Revenues ($m), 2003-2010
• Table 4.13 World Wellbutrin Revenues ($m), 2003-2010
• Table 4.14 World Remeron Revenues ($m), 2003-2010
• Table 5.1 US Revenues ($m) for Antidepressants, 2002-2004
• Table 5.2 US Prescription Numbers (m) for Antidepressants, 2002-2004
• Table 5.3 Percentage of Prescriptions for Generic and Branded Antidepressants (US) 2002-2004
• Table 5.4 Average Cost ($/unit) of Antidepressant Prescriptions (US), 2004
• Table 5.5 Generic Prescriptions (US) for Leading Antidepressants, 2004
• Table 5.6 Generic Revenues (US) for Leading Antidepressants, 2004
• Table 6.1 Major Antidepressant Drug Classes and Common Side Effects, 2005
• Table 7.1 Triple Uptake Inhibitors in the Developmental Pipeline, 2005
• Table 7.2 5HT Agonists in the Developmental Pipeline, 2005
• Table 7.3 Neurokinin Receptor Antagonists in the Developmental Pipeline, 2005
• Table 7.4 CRF Receptor Antagonists in the Developmental Pipeline, 2005
• Table 7.5 Antidepressants with Other Modes of Action in the Developmental Pipeline, 2005
• Table 8.1 The Substantial Influence of Patent Loss on the Antidepressant Market, 2005

List of Figures

• Figure 4.1 Total World Revenues for Antidepressants, 2003-2010
• Figure 4.2 World Revenues for Leading Antidepressants, 2004 and 2010
• Figure 4.3 Market Share (%) for Antidepressants, 2004
• Figure 4.4 Market Share (%) for Antidepressants, 2010
• Figure 4.5 Cost of Antidepressants, 2005
• Figure 4.6 Price Comparison of Branded and Generic Antidepressants, 2005
• Figure 4.7 World Market Share (%) by Drug Class, 2004
• Figure 4.8 World Market Share (%) by Drug Class, 2010
• Figure 4.9 World Revenues($m) for Zoloft, 2003-2010
• Figure 4.10 World Revenues ($m) for Paxil, 2003-2010
• Figure 4.11 World Revenues ($m) for Celexa and Lexapro, 2003-2010
• Figure 4.12 World Revenues ($m) for Prozac, 2003-2010
• Figure 4.13 World Revenues ($m) for Luvox, 2003-2010
• Figure 4.14 World Revenues($m) for Effexor, 2003-2010
• Figure 4.15 World Revenues ($m) for Cymbalta, 2003-2010
• Figure 4.16 World Revenues ($m) for Wellbutrin, 2003-2010
• Figure 4.17 World Revenues ($m) for Remeron, 2003-2010
• Figure 4.18 World Market Share (%) by Company, 2004
• Figure 4.19 World Market Share (%) by Company, 2010
• Figure 5.1 World Revenues ($m) for Antidepressant by Country/Region, 2004
• Figure 5.2 Revenues ($m) for US Antidepressants, 2004
• Figure 5.3 Prescriptions for US Branded and Generic Antidepressants, 2002-2004
• Figure 5.4 US Prescription Trends for Antidepressants, 2002-2004
• Figure 5.5 Percentage of US Prescriptions for Generic and Branded Antidepressants, 2002
• Figure 5.6 Percentage of US Prescriptions for Generic and Branded Antidepressants, 2004
• Figure 5.7 Average Cost ($/unit) of Antidepressants, 2004
• Figure 5.8 Willingness to Seek Help for Mental Health Disorders in Europe
• Figure 5.9 World Revenue ($m) for Antidepressant by Country in Europe, 2004
• Figure 6.1 A SWOT Chart for the Antidepressant Market, 2005
• Figure 7.1 Antidepressant Market in Relation to Major Patent Losses, 2004-2010